Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study of Long-Acting Cabotegravir Plus VRC01LS to Maintain Viral Suppression in HIV-1-Infected Adults

Trial Profile

A Study of Long-Acting Cabotegravir Plus VRC01LS to Maintain Viral Suppression in HIV-1-Infected Adults

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Feb 2019

At a glance

  • Drugs Cabotegravir (Primary) ; Cabotegravir (Primary) ; VRC 01LS (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Jan 2019 Planned End Date changed from 30 Sep 2021 to 29 Mar 2022.
    • 26 Dec 2018 Planned initiation date changed from 31 Jan 2019 to 15 Mar 2019.
    • 22 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top